Prima BioMed Announces First Clinical Data From Combination of IMP321 With Anti-PD1
December 29, 2016 04:04 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Dec 29, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") today announced interim data for its TACTI-mel (Two ACTive Immunotherapeutics...
Prima BioMed Announces Data From IMP321 AIPAC Clinical Trial in Breast Cancer
December 21, 2016 16:33 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Dec 21, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") today announced interim data from the AIPAC Phase IIb clinical trial for...
Prima BioMed Receives UK Approval for AIPAC Study
December 19, 2016 19:00 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Dec 19, 2016) -
Competent Authority and Ethics Committee approval received in the United Kingdom for AIPAC
Recruitment...
Prima BioMed Announces ADR Ratio Change
December 18, 2016 18:39 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Dec 18, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") announces a ratio change for the Company's American Depositary Receipt ("ADR")...
Prima to Present at 2016 Society for Immunotherapy of Cancer Conference
October 12, 2016 21:36 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Oct 12, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima") announces that the submission titled "LAG-3Ig (IMP321) in combination with anti-PD-1 therapy"...
Prima Abstracts Accepted for Poster Presentation at ESMO Symposium on Immuno-Oncology
October 06, 2016 01:54 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Oct 6, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") announces that an abstract for each of its two clinical trials for IMP321 has...
European Patent Grants for IMP731 Antibody
August 24, 2016 20:34 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Aug 24, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") announces the granting of patent number 2142210 entitled "Cytotoxic anti-LAG-3...
Prima BioMed Ltd: Operational Update
August 18, 2016 05:00 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Aug 18, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD), has provided an update on the Company's cash position and the recruitment progress in its two active...
Prima BioMed Receives NASDAQ Notice of Bid Price Deficiency
August 10, 2016 03:54 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Aug 10, 2016) - Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima", the "Company"), has received notification from the Listing Qualifications Department of The...
Prima BioMed Collaborates in Investigator Sponsored New Clinical Trial for IMP321 in Solid Tumors
July 12, 2016 03:37 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Jul 12, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) today announced a new collaborative study investigating the intra-tumoural injection of IMP321. The...